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Abstract
Background: Nilotinib inhibits the tyrosine kinase activities of ABL1/BCR-ABL1, KIT, and platelet-derived growth
factor receptors (PDGFRs). The results of a phase III clinical trial indicated that nilotinib could not be recommended
for broad use as first-line therapy for gastrointestinal stromal tumor (GIST). However, some clinical studies have
reported the effectiveness of nilotinib. We report here the cases of two patients who underwent surgical resections
of nilotinib-resistant lesions after long-term nilotinib administration.
Case presentation: Two Japanese female patients, aged 66 and 70 years, experienced peritoneal recurrence of
intestinal GIST several years after surgery. Both were registered in the ENESTg1 trial and received nilotinib therapy.
Although they continued nilotinib administration with a partial response according to the protocol, nilotinib-
resistant lesions, which were diagnosed as focally progressive disease, developed and complete surgical resection
was performed. Pathological examination revealed that the tumors were composed of viable KIT-positive spindle
cells, and the recurrent tumors were diagnosed as nilotinib-resistant GIST. In gene mutation analysis, a secondary
KIT gene mutation was detected in one case. Both patients have survived more than 5 years after the first surgery.
Conclusions: Of patients who were registered in this trial, we have encountered two patients with long-term
effects after nilotinib administration. Moreover, secondary mutations in the KIT gene, similar to those involved in
resistance to imatinib, might be involved in resistance to nilotinib.
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Background
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal neoplasms of the gastrointestinal
tract [1–4]. In 2000, imatinib, a selective tyrosine kinase
inhibitor (TKI), was introduced for GIST therapy [5].
Since then, the prognoses of patients with unresectable
and metastatic GIST have dramatically improved [6–9].
Worldwide, imatinib is the standard first-line therapy for
patients with GISTs that are metastatic, unresectable, or
both. However, despite such high clinical efficacy, ima-
tinib treatment cannot achieve complete disease control.
Nearly 90% of patients undergoing imatinib therapy
experience disease progression following a significant re-
sponse despite treatment continuation. Various treat-
ments are available for patients with secondary imatinib
resistance. In cases with limited progression wherein
there are few lesions with a limited distribution, local
therapies, including surgical resection, have been effect-
ive [10–12]. Moreover, gene mutation analysis revealed
that lesions acquired resistance via secondary KIT muta-
tions in addition to primary KIT mutations. Acquired
resistance to imatinib is most commonly caused by sec-
ondary KIT mutations in other exons that arise during
tyrosine kinase inhibitor therapy [6, 13–17].
Nilotinib is a selective tyrosine kinase inhibitor that
targets ABL1, BCR-ABL, KIT, PDGFRα and PDGFRβ,
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and DDR-1 and DDR-2. Nilotinib has in vitro inhibitory
activity similar to that of imatinib against KIT and plate-
let-derived growth factor receptors (PDGFRs) [18–20].
A phase III trial (ENESTg1) was performed to clarify
the efficacy and safety of nilotinib compared to ima-
tinib as first-line therapy for patients with advanced
GISTs. In these trial results, although tolerance to niloti-
nib was similar to that of imatinib, nilotinib treatment
failed to show superiority based on the primary end point
of progression free-survival [21]. Because of this, nilotinib
could not replace imatinib as first-line therapy for meta-
static GIST. However, we have encountered two patients
who have experienced long-term effects after nilotinib ad-
ministration in the ENESTg1 trial and showed focal resist-
ance. We resected each resistant lesion and continued
molecular targeting therapy.
In this report, we assessed the therapeutic strategy and
mechanism of nilotinib resistance.
Case presentation
Patient 1
A 76-year-old woman was diagnosed with a small intes-
tinal primary GIST and underwent partial jejunum re-
section via open surgery. The tumor stained positively
for CD117 (KIT) and CD34, and it was composed of
spindle cells with >5 mitoses/50 high-power fields
(HPF). Gene mutation analysis revealed a Lys (AAG)
558 to Asn&Pro (AACCCG) KIT mutation in exon 11.
Postoperatively, she was followed-up strictly without ad-
juvant therapy. Two years after operation, a 15-mm peri-
toneal metastasis was discovered in the mesentery
(Fig. 1a). We informed her of the randomized phase III
trial (ENESTg1), and she agreed to enroll in the trial.
After assignment to the nilotinib arm, she was treated
with nilotinib. Because of several adverse events, includ-
ing grade 2 appetite loss and skin bruising, she
continued this treatment for 57 months at a decreased
nilotinib dose according to the protocol guidelines and
achieved a partial response (Fig. 1b).
Fifty-seven months after nilotinib administration, she
experienced abdominal distention and vomiting. From
imaging examinations, she was diagnosed with ileus due
to a recurrent tumor (Fig. 1c). Since we diagnosed her
with focal resistance, she underwent surgical tumor re-
section (Fig. 2a and b). Pathological examination re-
vealed that the tumor was composed of viable spindle
cells with 15 mitoses/50 HPF that stained positively for
CD117 (KIT) and CD34 (Fig. 2c–f ). From the above
findings, we diagnosed the patient with recurrent
nilotinib-resistant GIST. According to gene mutation
analysis, the resistant GIST contained the same genetic
KIT mutation in exon 11 observed in the primary GIST
without any secondary mutations. After an additional
surgery, nilotinib administration has been continued for
21 months, with no evidence of recurrence.
Patient 2
Similar to the patient in case 1, a 66-year-old woman
was diagnosed with a primary submucosal tumor in the
small intestine and underwent partial jejunum resection
via open surgery. The tumor stained positively for
CD117 (KIT) and was composed of spindle cells with 19
mitoses/50 HPF. From the above findings, tumor was
finally diagnosed as a GIST originating from the small
intestine. Gene mutation analysis revealed a Del-5a.a
(557-561) KIT mutation in exon 11. She received post-
operative adjuvant imatinib (400 mg daily) for 1 year. As
adverse events of imatinib, she experienced leukopenia
(grade 3), thrombopenia (grade 2), and leg edema
(grade 1). Four years after the operation, a 77-mm
peritoneal metastasis was discovered (Fig. 3a). We in-
formed her of the randomized phase III trial (ENESTg1),
Fig. 1 Case 1 imaging findings. a Abdominal CT at study enrollment. b Abdominal CT 3 months after start of nilotinib therapy. c Abdominal CT
of the developing nilotinib-resistant tumor
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Fig. 2 Case 1 surgical and pathological images. a, b Intraoperative photography. c Hematoxylin and eosin staining (×400). d–f Immunohistochemical
staining of KIT/CD117 (d), CD34 (e), and MIB-1 (f) (×400)
Fig. 3 Case 2 imaging findings. a Abdominal CT at study enrollment. b Abdominal CT 3 months after start of nilotinib therapy. c Abdominal CT
(C-1) and PET-CT (C-2) of the developing nilotinib-resistant tumor
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and she agreed to enroll. After assignment to the nilotinib
arm, she was treated with nilotinib. She experienced no
adverse events. She continued this treatment with a partial
response for 41 months, according to the protocol guide-
lines (Fig. 3b).
Forty-one months after nilotinib administration, an ab-
dominal computed tomography (CT) scan showed a 55-
mm enhanced tumor area in the tumor margin, and
fluorodeoxyglucose (FDG) accumulation was observed
in the tumor margin by positron emission tomography-
CT (PET-CT) (Fig. 3c). Because her tumor exhibited
focal progression, she underwent surgical tumor resec-
tion (Fig. 4a and b). Pathological examination revealed a
tumor composed of viable spindle cells with 34 mitoses/
50 HPF and positive CD117 (KIT) staining (Fig. 4c–f ).
From the above findings, we diagnosed the patient with
recurrent nilotinib-resistant GIST. According to gene
mutation analysis, the resistant GIST contained not
only the primary genetic KIT mutation in not only
exon 11 but also secondary KIT mutation in exon 13
(Asn655Thr). After an additional surgery, since the
nilotinib clinical trial was complete, we suggested that
the patient receive imatinib therapy. However, the pa-
tient opted for observation only because of adverse
events due to imatinib therapy. Sixteen months after
reoperation, an abdominal CT scan showed multiple
peritoneal metastases. Imatinib (300 mg daily) was ad-
ministered for recurrence, and the patient now has
stable disease (SD).
We summarized the main characteristics of two cases
with nilotinib therapy in Table 1.
Discussion
Nilotinib is a selective tyrosine kinase inhibitor that tar-
gets ABL1, BCR-ABL1, KIT, PDGFRα and PDGFRβ, and
DDR-1 and DDR-2. It has in vitro inhibitory activity
similar to that of imatinib against KIT and PDGFRs
[18–20]. For chronic myelogenous leukemia (CML), a
phase III randomized controlled trial showed the ben-
efits of first-line nilotinib treatment compared to ima-
tinib [22]. Currently, nilotinib is a first-line treatment
for CML according to the National Comprehensive
Cancer Network (NCCN) guidelines [23]. Since the
same effect as CML has been expected for GIST, clinical
trials comparing nilotinib with imatinib have been per-
formed. Previously, nilotinib was reported to be efficacious
in imatinib- and/or sunitinib-resistant GIST [24–27]. The
randomized multi-center phase III ENESTg1 trial was per-
formed to compare imatinib and nilotinib as first-line
treatment for distant metastasis or unresectable GIST
[21]. In this trial, 647 people were registered, and patients
demonstrated good tolerance to nilotinib compared with
imatinib. However, nilotinib did not exhibit superiority in
the progression-free survival (PFS) as the primary end-
point, with a PFS of 25.9 months in the nilotinib group vs.
29.7 months in the imatinib group. In addition, in sub-
group analysis, patients with exon 11 mutations had better
prognosis in overall survival or PFS both imatinib and
nilotinib treatment group. In the present cases, the two
patients with primary GISTs who participated in the
ENESTg1 trial also had KIT mutations in exon 11, sug-
gesting that long-term control of disease progression
might be possible.
Fig. 4 Case 2 surgical and pathological images. a, b Intraoperative photography. c Hematoxylin and eosin staining (×400). d–f Immunohistochemical
staining of KIT/CD117 (d), CD34 (e), and MIB-1 (f) (×400).
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For patients with imatinib-resistant GIST, although su-
nitinib is recommended as treatment, surgery and con-
tinued imatinib therapy have been effective against
focally progressive disease [11, 12, 28, 29]. Hasegawa et
al. reported that patients with imatinib-resistant GISTs
that are small, have few foci, and are of gastric origin
might benefit from surgery plus continued imatinib ther-
apy, with considerable tolerance and safety [30]. Add-
itionally, in the two cases mentioned here, since the
patients had good disease control after long-term niloti-
nib administration and no distant metastasis, similar to
the therapeutic strategy for imatinib-resistant GIST, sur-
gical resection was a good option. From pathological
examination, we noted positive KIT staining, which was
also similar to that seen in imatinib-resistant GIST. Pa-
tient 1, who underwent complete surgical resection and
continued nilotinib therapy, has lived for 21 months
with no recurrence.
In imatinib-resistant lesions, secondary KIT mutations
were usually acquired in addition to primary KIT muta-
tions [10–12]. Nishida et al. reported that 33 out of 45
tumors (73%) harbored secondary KIT mutations in the
KIT kinase domain in GIST patients treated with ima-
tinib therapy [13]. In case 2, in which the lesion devel-
oped resistance during nilotinib administration for
recurrent GIST in addition to the primary KIT mutation
in exon 11, the resistant lesion had a secondary KIT mu-
tation in exon 13. Secondary mutations may lead to nilo-
tinib resistance, similarly to those involved in imatinib
resistance.
In GISTs showing secondary resistance to imatinib, a
particular Val654Ala mutation has been detected as the
exon 13-type secondary c-kit gene mutation. On the
other hand, Asn655Thr mutation at exon 13 of the c-kit
gene was observed as a secondary mutation in case 2
with secondary resistance to nilotinib. Kinoshita et al.
reported that Asn655Lys mutation at exon 13 which was
observed as a primary mutation in a sporadic GIST was
imatinib-sensitive [31]. Since the codon number in
Asn655Thr and Asn655Lys is the same, there is a possi-
bility that Asn655Thr mutation in the present case 2
might be nilotinib-resistant but imatinib-sensitive. How-
ever, the properties of resistance to imatinib and niloti-
nib might be different from each other in Asn655Thr
and Asn655Lys because the substituted amino acid is
different between them. Effectiveness of imatinib in
Asn655Thr remains to be clarified.
Conclusions
The results of the ENESTg1 trial indicated that nilotinib
cannot be recommended instead of imatinib for broad
use as first-line treatment for patients with distant me-
tastasis or unresectable GIST. Of patients who were reg-
istered in this trial, we have encountered two patients
with long-term effects after nilotinib administration.
Moreover, with regard to nilotinib resistance, secondary
KIT mutations might be involved, similarly to those in-
volved in imatinib resistance.
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